Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC (GRAN-T-MTC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03246659|
Recruitment Status : Recruiting
First Posted : August 11, 2017
Last Update Posted : August 16, 2017
The study is a phase I multicentre randomized, open, parallel-arm clinical trial conducted to investigate the IMP, namely 111In-CP04.
The study consists of preclinical (to establish a clinically useful formulation for the radiolabelled peptide CP04), and a clinical step. The main objective of the clinical part of the project is to establish the safety of i.v. administration of a high peptide amount and to assess the tracer biodistribution and dosimetry in MTC and normal tissues and to determine critical organs as well as the evaluation of the potential of CCK2 receptor scintigraphy to detect cancer lesions for both low (10ug) and high (50ug) peptide amount and the decrease of kidney dose after co-administration of gelofusine /gelaspan as a nephroprotective agent. To achieve this, the following study design has been accepted: the first 4 patients will receive 2 peptide amount of CP04: low peptide amount (for diagnostic purpose) and high peptide amount (for therapeutic purpose) of CP04. If no SAE is present, the remaining pts will be randomized for 2 arms: high peptide amount of 111In-CP04 with and without gelofusine/gelaspan infusion.
It is expected that CCK-2/gastrin receptor imaging will become a valid diagnostic method for a specific non-invasive staging and follow-up of patients with MTC, and treatment of recurrent and disseminated disease will be more efficient with minimized nephro- and myelotoxicity (if 111In labelled).
|Condition or disease||Intervention/treatment||Phase|
|Medullary Thyroid Carcinoma||Drug: 111In-CP04 Drug: 111In-CP04 with co-administration of gelofusine/gelaspan||Phase 1|
The main goal of the study is to expand cancer preclinical research results on the usefulness of CCK-2/gastrin receptor in clinical practice. On the basis of last few years preclinical research outcome on new biomarkers, conjugate CP04 was chosen on the basis of its good stability and affinity to CCK-2/gastrin receptor in vitro, as well as its favourable biodistribution and pharmacodynamic properties in vivo, preclinically. Within this project the tracer may get a chance to be introduced to clinical practice as a more selective and efficient tool for the diagnosis, early detection and therapy of recurrent and metastatic MTC.
Furthermore, the project may become the first step to establish a new, more effective strategy for the treatment of MTC patients leading to reduction of incidence and mortality as well as improvement of quality of life. CCK-2/gastrin receptors may become viable targets for radionuclide scintigraphy and radionuclide therapy, similarly to somatostatin receptors which have been instrumental to establish nuclear medicine efficacy in clinical practice. Achieving key project objectives (i.e. investigation of patients after administration of high peptide amount of the CCK-2/gastrin receptor labelled compound, performing complete patient peptide assessment and research nephrotoxicity in patients with or without administration for nephroprotective agent gelofusine/gelaspan), we will be able to define the exact molecular profile of an individual patient and tumour. Eventually, safe and efficacious personalized treatment will be planned using radiolabelled CCK-2/gastrin ligands of higher therapeutic efficacy.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||25 participants|
|Intervention Model:||Sequential Assignment|
|Official Title:||Phase I Clinical Trial Using a Novel CCK-2/Gastrin Receptor-localizing Radiolabelled Peptide Probe for Personalized Diagnosis and Therapy of Patients With Progressive or Metastatic Medullary Thyroid Carcinoma|
|Actual Study Start Date :||August 2016|
|Estimated Primary Completion Date :||November 2018|
|Estimated Study Completion Date :||November 2018|
Experimental: arm 1
Other Name: 111In-CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2
Experimental: arm 2
111In-CP04 with co-administration of gelofusine/gelaspan
Drug: 111In-CP04 with co-administration of gelofusine/gelaspan
Radiopharmaceutical preparation with co-administration of gelofusine/gelaspan
Other Name: 111In-CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of CP04 [ Time Frame: 4 months ]Safety of intravenous administration of CP04 at low peptide amount (for diagnostic purpose) and high peptide amount (for therapeutic purpose) radiolabelled with 200±10% MBq of 111In will be assessed by type, frequency, severity, timing and relation to the studied radiopharmaceutical Safety of intravenous administration of CP04 at low peptide amount (for diagnostic purpose) and high peptide amount (for therapeutic purpose) radiolabelled with 200±10% MBq of 111In will be assessed by type, frequency, severity, timing and relation to the studied radiopharmaceutical administration of adverse events and laboratory abnormalities based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Uptake of 111In-CP04 in tumor and other tissues [ Time Frame: 72 hours from 111In-CP04 injection ]The radioactivity uptake of 111In-CP04 will be assessed in the tumor lesions and in other tissues naturally expressing CCK2 receptors, based on the planar and SPECT/CT images (expressed as the ratio of counts over the region of interest (ROI) selected over the target tissue compared to the counts over the equivalent region in patient's body which is not taking up the 111In-CP04), otherwise described as target to non target ratio T/N
- Pharmacokinetics of 111In-CP04 [ Time Frame: 72 hours from 111In-CP04 injection ]Area under the selected organs concentration versus time curve
- Pharmacokinetics of 111In-CP04 [ Time Frame: 72 hours from 111In-CP04 injection ]Area under the blood concentration versus time curve
- Diagnostic sensitivity/specificity of 111In-CP04 to detect cancer lesions [ Time Frame: 3 years ]Diagnostic sensitivity/specificity of 111In-CP04 to detect cancer lesions for both diagnostic and therapeutic peptide amount by Qualitative Visual Analysis (number of patients with uptake at site of lesion, the number of lesions with abnormal tracer uptake at scintigraphy, the number and site of lesions with pathological uptake detected per verifiable organ or body region relative to those detected
- Comparison of pharmacokinetic/imaging effect of low and high peptide amount [ Time Frame: 3 years ]To evaluate the influence of a low amount of CP04 peptide on the high amount of peptide vs. the high amount of peptide alone on tumour and organ uptake
- Gelofusine/gelaspan injection and CP04 kidney uptake [ Time Frame: 3 years ]To investigate the relative decrease of kidney dose after co-administration of nephroprotective agent - gelofusine/gelaspan
- Dosimetry [ Time Frame: 72 hours from 111In-CP04 injection ]Pharmacokinetics data for the assessment of organ and tissue radiation absorbed doses..
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03246659
|Contact: Alicja Hubalewska-Dydejczyk, Professor||0048 12 424 75 email@example.com|
|Contact: Paola Anna Erba, Professor||00 39 050 992 firstname.lastname@example.org|
|Department of Nuclear Medicine, Innsbruck Medical University||Recruiting|
|Contact: Irene Virgolini, Professor 0043 125 048 0951 email@example.com|
|Contact: Clemens Decristoforo, Professor 0043 125 048 0951 Clemens.Decristoforo@tirol-kliniken.at|
|Principal Investigator: Irene Virgolini, Professor|
|Department of Nuclear Medicine, University Hospital Freiburg||Not yet recruiting|
|Contact: Helmut Mäcke, Professor 0049 761 270 74220 Helmut.firstname.lastname@example.org|
|Principal Investigator: Helmut Mäcke, Professor|
|Erasmus University Rotterdam||Not yet recruiting|
|Contact: Marion Hendriks-de Jong, Professor 0031107035781 email@example.com|
|Contact: Mark Konijnenberg, PhD 0031107035781 firstname.lastname@example.org|
|Principal Investigator: Marion Hendriks-de Jong, Professor|
|Department of Endocrinology, Jagiellonian University Medical College||Active, not recruiting|
|Department of Nuclear Medicine, University Medical Centre Ljubljana||Recruiting|
|Contact: Katja Zalatel, doc.dr. 0038 615 223 553 email@example.com|
|Contact: Petra Kolenc Peitl, PhD firstname.lastname@example.org|
|Principal Investigator: Katja Zalatel, doc.dr.|
|Principal Investigator:||Paola Anna Erba, Professor||Azienda Ospedaliero, Universitaria Pisana|